Abstract: Modified natural killer cells, pharmaceutical compositions comprising the modified natural killer cells and at least one pharmaceutically acceptable carrier or excipient, uses of the modified natural killer cells, and methods for identifying depleted natural killer cells and culturing the modified natural killer cells are provided.
Abstract: The present invention relates to use of TRAF-interacting protein with an FHA domain (TIFA) antagonists for treating diseases. Particularly, the present invention relates to an isolated peptide fragment from TIFA which acts as a dominant negative inhibitor of TIFA and is effective in treating cancer or an inflammatory disorder. The present invention also relates to a method for predicting cancer prognosis based on the TIFA expression level in a subject in need. The present invention further relates to a method for treating a disease via TIFA silencing.
Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
Type:
Application
Filed:
August 24, 2018
Publication date:
January 24, 2019
Applicants:
ACADEMIA SINICA, KAOHSIUNG MEDICAL UNIVERSITY
Inventors:
STEVEN R ROFFLER, TIAN-LU CHENG, CHIEN-HAN KAO, BING-MAE CHEN, YU-CHENG SU, HSIN-YI TUNG, Kuo-Hsiang Chuang
Abstract: The present invention provides a recombinant DNA molecule encoding a fusion protein, comprising a first DNA sequence encoding a high-efficiency transit peptide operably linked to a second DNA sequence encoding a passenger protein, wherein the high-efficiency transit peptide is selected from the group consisting of transit peptides of the precursors of translocon at the inner envelope membrane of chloroplasts 40 kD (prTic40), chaperonin 10-2 (prCpn10-2), Fibrillin 1B (prFibrillin), ATP sulfurylase 1 (prAPS1), ATP sulfurylase 3 (prAPS3), 5?-adenylylsulfate reductase 3 (prAPR3), stromal ascorbate peroxidase (prsAPX), prTic40-E2A (a prTic40 variant), prCpn10-1-?C7C37S (a chaperonin 10-1 variant), a functional fragment of any of the transit peptides and an equivalent thereof. And the present invention also provides a method of high efficiency delivery of a protein into plastids using the high-efficiency transit peptides.
Abstract: Disclosed herein is a method of treating influenza A virus (IAV) infection by a fusion protein. According to some embodiments of the present disclosure, the fusion protein comprises a HBD peptide and a IgG1 Fc region. According to other embodiments of the present disclosure, the fusion protein comprises a DcR3 protein and a IgG1 Fc region. The present fusion protein is found to possess inhibitory effects on IAV-induced secretion of the inflammatory cytokine, and IAV-induced infiltration of inflammatory cell into the lung tissue. Accordingly, the fusion protein is useful for developing a medicament for the treatment or prophylaxis of IAV infection and/or ameliorating pulmonary injury caused by excessive inflammation associated with IAV infection in a subject.
Abstract: A composition comprising a therapeutically effective amount of Bidens pilosa extract, or an active compound isolated from the Bidens pilosa extract for use in treating obesity, reducing body weight or body weight gain, and/or gaining muscle mass or muscle content in a subject in need thereof is disclosed. The composition is useful for reducing fat cell size and/or fat accumulation in the fat cell in a subject in need thereof. The composition may further comprises an animal feed. A polyacetylenic compound for use in treating obesity, gaining muscle mass or muscle content, and/or increasing lean tissue protein content in a subject in need thereof is also disclosed. In one embodiment, the polyacetylenic compound is cytopiloyne.
Abstract: The present disclosure provides compounds of Formulas (I?) and (I), and pharmaceutically acceptable salts thereof. The compounds described herein may be useful in treating and/or preventing proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, and uses thereof for treating proliferative diseases.
Type:
Application
Filed:
February 3, 2017
Publication date:
December 27, 2018
Applicants:
Academia Sinica, National Taiwan University
Inventors:
Chi-Huey Wong, Pan-Chyr Yang, Jim-Min Fang, Szu-Hua Pan, Ting-Jen R. Cheng, Ling-Wei Li
Abstract: The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.
Abstract: This disclosure includes an immunogenic composition containing (a) a glycan conjugate including a carrier and one or more glycans, wherein each of the one or more glycans is conjugated with the carrier through a linker, and optionally (b) an adjuvant. The one or more glycan is each a Globo H derivative.
Type:
Grant
Filed:
August 21, 2015
Date of Patent:
December 18, 2018
Assignee:
ACADEMIA SINICA
Inventors:
Chi-Huey Wong, Chung-Yi Wu, Hsin-Yu Lee
Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.
Abstract: An engineered enzyme, comprising an amino acid sequence that is at least 80% identical to the amino acid sequence of a human beta-glucuronidase, wherein the engineered enzyme exhibits a higher level of alpha-iduronidase enzymatic activity as compared to the human beta-glucuronidase.
Abstract: Novel dual-targeted, bifunctional anti-influenza drugs formed by conjugation with anti-inflammatory agents are disclosed. Exemplary drugs according to the invention include caffeic acid (CA)-bearing zanamivir (ZA) conjugates ZA-7-CA (1), ZA-7-CA-amide (7) and ZA-7-Nap (43) for simultaneous inhibition of influenza virus neuraminidase and suppression of proinflammatory cytokines. Synthetic methods for preparation of these enhanced anti-influenza conjugate drugs are provided. The synthetic bifunctional ZA conjugates act synergistically towards protection of mice lethally infected by H1N1 or H5N1 influenza viruses. The efficacy of ZA-7-CA, ZA-7-CA-amide and ZA-7-Nap conjugates is much greater than the combination therapy of ZA with anti-inflammatory agents.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
November 20, 2018
Assignee:
ACADEMIA SINICA
Inventors:
Chi-Huey Wong, Jim-Min Fang, Kung-Cheng Liu, Jia-Tsrong Jan, Yih-Shyun E. Cheng, Ting-Jen R. Cheng
Abstract: The present invention relates to a method of improving stress tolerance and/or preventing growth reduction of a plant by introducing a polynucleotide encoding a Repetitive Proline-rich Protein (RePRP) into the plant.
Type:
Application
Filed:
March 16, 2018
Publication date:
November 8, 2018
Applicant:
Academia Sinica
Inventors:
Tuan-Hua HO, I-Chieh TSENG, Su-May YU, Shuen-Fang LO
Abstract: The present disclosure relates to compositions and methods of use comprising antibodies or binding fragments thereof further comprising universal Fc glycoforms.
Type:
Grant
Filed:
January 30, 2016
Date of Patent:
November 6, 2018
Assignee:
ACADEMIA SINICA
Inventors:
Chi-Huey Wong, Chung-Yi Wu, Che Ma, Han-Chung Wu
Abstract: Provided are azido-BODIPY compounds of formula (I), cyclooctyne-based fluorogenic probes of formula (IV), and activity-based probes of formula (VI). These compounds undergo azide-alkyne cycloadditions (AAC) with to form triazolyl products. The provided compounds are useful for detection and imaging of alkyne-, or azide-containing molecules. Methods for detection and imaging biomolecules using compounds of the present disclosure are disclosed.
Abstract: Methods for treating pain such as fibromyalgia, comprising administering to a subject in need thereof an effective amount of an adenosine analog, wherein the adenosine analog may be a compound of Formula (I): (I), or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising the adenosine analog for use in treating pain (e.g., fibromyalgia), optionally further comprising Substance P (SP), are also provided.
Type:
Grant
Filed:
December 12, 2016
Date of Patent:
November 6, 2018
Assignee:
Academia Sinica
Inventors:
Chih-Cheng Chen, Yun-Lian Lin, Jim-Min Fang, Yijuang Chern, Chia-Ching John Lin, Wei-Nan Chen, Chun-Jung Lin
Abstract: Glycosphingolipids (GSLs) bearing ?-glucose (?-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with ?-glucose (?-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with ?-galactose (?-Gal) are disclosed. GSLs bearing ?-glucose (?-Glc) and derivatives of ?-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with ?-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with ?-Glc and derivatives thereof are provided.
Type:
Grant
Filed:
August 29, 2017
Date of Patent:
October 30, 2018
Assignee:
ACADEMIA SINICA
Inventors:
Chi-Huey Wong, Alice L. Yu, Kun-Hsien Lin, Tai-Na Wu
Abstract: A mutant of Endos2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO:1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.
Abstract: Disclosed herein are kits comprising transcription factors for inducing a fibroblast cell into an induced embryonic neural progenitor cell. The induced embryonic neural progenitor cell is then capable of differentiating into an astrocyte, an oligodendrocyte or a neuron. Also disclosed are the uses of the kit as a platform for selecting a drug candidate to treat neurological diseases.